Adeno-associated virus gene transfer into renal cells: Potential for in vivo gene delivery

Jessica C. Langer, Mary E. Klotman, Basil Hanss, Natalie Tulchin, Leslie A. Bruggeman, Paul E. Klotman, Michael S. Lipkowitz

Research output: Contribution to journalShort surveypeer-review

9 Scopus citations

Abstract

The human parvovirus adeno-associated virus (AAV), type 2, has a number of features that make it an attractive choice as a vector for gene delivery to the kidney. AAV vectors permit long-term gene expression in vivo by integration into the host genome, have potential for site-specific integration of chromosome 19, do not express viral genes or generate a cellular immune response, and demonstrate enhancement of gene expression by chemotherapeutic agents that are approved for use in vivo. These properties confer advantages to AAV over other viral and nonviral methods for gene transfer. Preliminary experiments in our laboratory suggest that AAV is able to transfer genes to both renal cells in culture and the kidney in vivo. Thus, AAV has the potential to be an important gene transfer vector for the kidney in vivo.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalExperimental Nephrology
Volume6
Issue number3
DOIs
StatePublished - 1998

Keywords

  • Adeno-associated virus vector
  • Gene therapy
  • Gene transfer
  • Liposomes

Fingerprint

Dive into the research topics of 'Adeno-associated virus gene transfer into renal cells: Potential for in vivo gene delivery'. Together they form a unique fingerprint.

Cite this